37 results about "Naproxenum" patented technology

The invention particularly relates to a method for determining a reaction rate constant of tetravalent iron and organic pollutants by using a chemiluminescence method, and belongs to the technical field of water quality detection. According to the method, on the basis of a chemiluminescence reaction between Fe (IV) and naproxen (NAP), a target organic pollutant (TrOC) is introduced, the quenching effect of the target organic pollutant on a chemiluminescence signal is measured, and a competitive kinetic model between the chemiluminescence quenching capacity (CLQC) and a secondary reaction rate constant (kFe (IV), TrOC) of Fe (IV) on the target pollutant is constructed. According to the method, the concentration of Fe (IV) does not need to be monitored in real time, and the reaction activity between Fe (IV) and various pollutants can be directly and rapidly measured only by comparing the intensity change of the chemiluminescence signals when the target pollutants exist and do not exist.

The present application relates to a kind of carbonized iron and nitrogen coordination iron co-doped nitrogen and graphene carbon material and preparation method and application, with six hydrated ferric chloride as iron source, with chitin as nitrogen, carbon source. By simple one-step method, after mixing, calcination, grinding way, carbonized iron and nitrogen coordination iron co-doped nitrogen and graphene carbon material is synthesized.The material prepared by the present application presents two-dimensional layered structure, after adding potassium hydrogen peroxodisulfate oxidant, the material can completely remove the active pharmaceutical ingredient naphthyl in water in a short time.Naproxen.The synthesis method proposed in the present application is simple and easy to operate, and the material performance is excellent, which can provide a new design idea for nitrogen coordination iron nanomaterial supported by carbon material, and be applied to the remediation of contaminated water.

A composition comprises an alkali metal salt of a first pharmaceutical ingredient; and a second pharmaceutical ingredient, wherein the second pharmaceutical ingredient is chemically incompatible with the first pharmaceutical ingredient, and the composition is an aqueous solution. The first active pharmaceutical ingredient can comprise ibuprofen or naproxen. The second pharmaceutical ingredient can comprise acetaminophen.

The present invention discloses a C2-symmetric chiral bisphosphine ligand and its application in asymmetric hydrogenation reactions. The synthesis of this new type of chiral bisphosphine ligand can be prepared starting from the chiral raw material Ugi's amine, through deprotonation, followed by a tandem reaction with phosphine chloride and Grignard reagent. The synthesis method is simple, with variable structures and easy to control. At the same time, the present invention discloses a catalyst formed by this new type of chiral bisphosphine ligand and metal, which exhibits excellent catalytic activity and stereoselectivity in asymmetric hydrogenation and can be applied to the preparation of chiral drugs such as ibuprofen, naproxen, and alfloprofen.

The present invention is directed to a pharmaceutical composition comprising a pharmaceutically effective amount of guaifenesin, naproxen and at least one further active which is selected to be an antitussive, a decongestant or an antihistamine.

An improved immediate release solid dosage form of naproxen with a certain particle size distribution for the intragranular portion, and a certain particle size distribution for the carbonate portion that allows naproxen to remain in solution and achieves fast dissolution and fast absorption of naproxen. The invention provides a naproxen dosage form that when administered to a human in a fasted state provides an average blood plasma naproxen concentration of at least 15-20 μg / ml in 10 minutes or less. The invention also provides a naproxen dosage form that when administered to a human in a fed state provides an average blood plasma naproxen concentration of at least 15-20 μg / ml in 50 minutes or less.

The invention provides a method for detecting nine antipyretic and analgesic drugs in feed, and belongs to the field of food safety detection. The method comprises the following steps: pretreating a feed sample to obtain a sample to be detected; detecting the nine antipyretic and analgesic drugs in the to-be-detected sample by adopting a liquid chromatography-mass spectrometry method; the nine kinds of antipyretic and analgesic medicines are antipyrine, phenylbutazone, acetaminophen, analgin, naproxen, diclofenac, indometacin, aspirin and ibuprofen. According to the pretreatment method provided by the invention, the problems of tedious steps, long consumed time and low accuracy of a detection result can be improved. By adopting liquid chromatography-mass spectrometry, simultaneous determination of multiple types of drugs can be realized, qualitative and quantitative analysis of multiple drugs can be rapidly and accurately completed in a short time, the timeliness requirement of actual detection is met, and the method can be used for feed quality safety monitoring.

A composition comprises an alkali metal salt of a first pharmaceutical ingredient; and a second pharmaceutical ingredient, wherein the second pharmaceutical ingredient is chemically incompatible with the first pharmaceutical ingredient, and the composition is an aqueous solution. The first active pharmaceutical ingredient can comprise ibuprofen or naproxen. The second pharmaceutical ingredient can comprise acetaminophen.

The present disclosure relates generally to topical analgesic compositions comprising nonsteroidal anti-inflammatory drugs, and more specifically to topical gel compositions of naproxen in combination with select neutralizing agents, thereby having enhanced skin permeation and skin retention properties as well as improved aesthetics upon application and drying.

The invention discloses a sulfur-doped bi-metal cobalt cerium oxide Fenton-like catalyst and a preparation method and application thereof.The sulfur-doped bi-metal cobalt cerium oxide Fenton-like catalyst is a sulfur-doped cobalt cerium composite oxide, and in the sulfur-doped bi-metal cobalt cerium oxide Fenton-like catalyst, the Co element content is 20-24 wt%, the Ce element content is 50-56 wt%, the O element content is 20-22 wt%, and the balance is a carrier. The content of the S element is 1-4 wt%. According to the sulfur-doped bimetallic cobalt cerium oxide Fenton-like catalyst disclosed by the invention, peroxyacetic acid is activated to generate organic oxygen free radicals, and 90.5% of moxifloxacin can be degraded within 15 minutes; and the composite material has a good degradation effect on pollutants of polycyclic aromatic compounds such as ofloxacin, gatifloxacin, norfloxacin, tetracycline, o-nitrophenol, naproxen and the like.

This invention relates to the fields of environmental and chemical technology, specifically to a nitrogen-modified activated carbon adsorbent material, its preparation method, and its applications. The invention employs an ammonium chloride solution impregnation method combined with high-temperature activation under a nitrogen inert atmosphere to modify the surface of pretreated granular activated carbon, increasing the content of basic groups on the activated carbon surface, thus preparing a nitrogen-modified activated carbon adsorbent material. Experimental results show that the prepared nitrogen-modified activated carbon exhibits high adsorption efficiency for carboxylic acid drug pollutants such as naproxen, ibuprofen, and diclofenac. The preparation conditions of this invention are mild, the operation steps are simple, the required reagents are inexpensive, and the safety is relatively high, making it suitable for the treatment of drinking water, sewage, and medical wastewater.

The invention discloses a composition for toothache and application thereof.The composition is prepared from 2-6 parts of anisodamine, 4-12 parts of dexamethasone, 200-600 parts of naproxen and 200-500 parts of metronidazole. Through reasonable raw material matching, the composition can treat toothache caused by pulpitis, apical apitis, periodontal abscess, tooth oscillation trauma or periodontal disease and the like; rapid pain relieving can be achieved within 10-20 min for the first time, the pain relieving effect is rapid, and toothache can be treated fundamentally and efficiently; in addition, the traditional Chinese medicine composition is also beneficial to restoring the activity of dental pulp and has an effective treatment effect on tooth renaturation pulpitis; in addition, the root canal can be assisted in treating non-recupable pulpitis or apicitis, and the root canal treatment effect is improved.

An object of the present application is to provide a pharmaceutical composition which improves the anti-inflammatory effect of loxoprofen. According to the present application, there is provided a pharmaceutical composition comprising: at least one selected from the group consisting of loxoprofen, salts thereof, and hydrates thereof, and at least one selected from the group consisting of diclofenac, naproxen, salts thereof, and hydrates thereof.

This invention discloses a chiral covalent organic framework composite membrane prepared by in-situ growth and its applications. This invention uses [NALC] as a reference. X -TAPB-DVA COF S As a functionalized material, a chiral covalent organic framework composite membrane was prepared by a secondary in-situ growth method using terephthalaldehyde (PAD) as the linker and 1,3,5-tris(4-aminophenyl)benzene (TAPB) as the nucleation site. This chiral covalent organic framework composite membrane can resolve enantiomers of mandelic acid, warfarin, naproxen, and ibuprofen, exhibiting a wide resolution range and stable resolution performance.

This invention discloses a method for preparing a cyclodextrin-ammonium acetate-naproxen ternary inclusion complex, comprising the following steps: mixing β-cyclodextrin, naproxen, and ammonium acetate in a molar ratio of 0.8-1.3:0.9-1.1:0.8-2.5 with a solvent; stirring the resulting mixture at 35-45°C for 0.5-2 hours; and then removing the solvent by evaporation, standing, and freeze-drying to obtain the ternary complex. This invention prepares a ternary inclusion complex using β-cyclodextrin, naproxen, and ammonium acetate, which significantly improves drug stability and water solubility, thus helping to enhance the bioavailability of naproxen and expand its application areas.

The invention discloses a method for detecting an impurity I in naproxen. A naproxen raw material medicine and 1, 2, 4, 5-tetracyanobenzene (TCBB) are fully ground and evenly mixed, then a fluorescence signal is detected under the 365 nm ultraviolet irradiation condition, if green fluorescence is generated, it is indicated that the raw material medicine contains the impurity I, and otherwise, it is indicated that the raw material medicine does not contain the impurity I. The fluorescent probe TCNB and the naproxen impurity I can generate specific intermolecular charge transfer interaction, so that a fluorescent signal is generated, and the visual impurity inspection of the naproxen impurity I is realized. According to the method, the probe and the naproxen impurity I can interact with each other through a grinding method which is simple, convenient and easy to operate, so that bright green fluorescence is generated, 0.1% of limited impurities can still be detected, and meanwhile, the probe cannot interact with naproxen, so that the detection of the impurity I is not interfered. Therefore, the impurity detection method provided by the invention has low detection limit, good specificity and anti-interference capability, can effectively analyze the trace impurity I in naproxen without pretreatment, and has a wide application prospect.

Here described is a pharmaceutical composition comprising a fill material comprising: a salt of one or more pharmaceutically active agents; and a lipid-based water-soluble surfactant. The fill material may further comprise a lipid-based oil and wetting agent. The lipid-based oil may be medium-chain triglycerides and the wetting agent may be lecithin.

The invention belongs to the field of RS-naproxen chiral resolution, and relates to a metal organic framework chiral separation membrane as well as a preparation method and application thereof. The preparation method of the metal organic framework chiral separation membrane comprises the steps that a chiral selection solution is evenly laid on a PVDF base membrane and then subjected to vacuum suction filtration, and the chiral selection solution is an aqueous solution containing hydroxypropyl-beta-cyclodextrin, sulfobutyl-beta-cyclodextrin, N-ethylaniline, diphenyl sulfoxide and alkali metal hydroxide; and heating the obtained membrane in a methanol steam environment, and washing with water to obtain the metal organic framework chiral separation membrane. The metal organic framework chiral separation membrane obtained by the method has good separation performance and stability when being used for chiral resolution of RS-naproxen.

The present invention relates to naproxen triazolethione derivatives or naproxen triazolethiol derivatives represented by structural formula I or II, preparation methods, pharmaceutical compositions, and their use in the preparation of novel coronavirus 3CL protease inhibitors. #imgabs0# wherein R is selected from the group consisting of hydrogen, deuterium, C1-C2 alkyl, C3-C7 straight-chain or C3-C7 branched alkyl; Z is selected from the group consisting of hydrogen, 6-methoxy, 5-chloro-6-methoxy, 5-amino-6-methoxy, and 6-ethoxy; and Y 1 、Y 2 and Y 4 is selected from the group consisting of: hydrogen, deuterium, C1-C2 alkyl, nitro, amino, fluorine, chlorine, bromine, iodine, hydroxyl, methoxy or ethoxy; Y 3 is selected from the group consisting of: hydrogen, deuterium, C1-C2 alkyl, hydroxy, ethoxy, nitro, amino, methylamino, dimethylamino, acetylamino, fluorine, chlorine, bromine or iodine; Y 5 Selected from: hydrogen, deuterium, C1-C2 alkyl, nitro, amino, fluorine, chlorine, bromine, iodine.

The application discloses a kind of advanced oxidation device and method for degrading new pollutants in water, the device includes reaction pool, ozone generator, sulfite storage tank, ozone generator is used to add ozone to reaction pool, sulfite storage tank is used to add sulfite to reaction pool;Reaction pool is equipped with water inlet and water outlet. When using, inject the water sample to be treated into reaction pool, start ozone generator, sulfite storage tank to carry out the addition of ozone and sulfite;The molar ratio of ozone and sulfite addition in reaction pool is 5:1~1:1, the molar ratio of new pollutant concentration in the water sample to be treated and ozone addition amount is: 1:10~1:100.The advanced oxidation system of ozone activated sulfite constructed by the application has high yield of sulfate radical and hydroxyl radical, and can rapidly degrade new pollutants within 5 minutes, and the degradation efficiency of new pollutants such as naproxen, sulfamethoxazole, carbamazepine, atrazine and chloramphenicol in water reaches more than 80%.

This invention relates to a method for resolving (+)-isomenthyl alcohol, comprising the following steps: under nitrogen protection, racemic isomenthyl alcohol, S-naproxen, and a solvent are added to a reaction vessel, stirred and heated to reflux, and reacted at a constant temperature to obtain a reaction solution containing (±)-isomenthyl alcohol-S-naproxen ester. The solution is then post-treated to obtain crude racemic isomenthyl alcohol-naproxen ester. The crude product is dissolved in methanol and crystallized by cooling to obtain a primary crystallization product. The primary crystallization product is subjected to a secondary crystallization by repeating the above crystallization steps, and optically pure (+)-isomenthyl alcohol-S-naproxen ester is collected. The (+)-isomenthyl alcohol-S-naproxen ester is dissolved in methanol, and an aqueous hydroxide solution is added. The mixture is stirred and hydrolyzed, and after removing the methanol, it is extracted with an organic solvent. The final product is then post-treated to obtain pure (+)-isomenthyl alcohol. Compared with existing technologies, this invention has advantages such as simple operation, mild reaction conditions, high product purity, and easy recovery of the resolving agent, effectively solving the problems of impurity encapsulation and easy configuration inversion in traditional resolving methods.

Coupling reaction is an important type of reaction for constructing carbon-carbon bonds or carbon-hetero bonds. Usually, this type of reaction needs to be carried out under the catalysis of transition metals and has good substrate tolerance. It is commonly used in the synthesis of various natural products and drug molecules. Drugs such as naproxen and ibuprofen with α-aryl propionate as the basic skeleton are an important class of non-steroidal anti-inflammatory drugs. This type of drug has the advantages of small toxic side effects and strong efficacy. For α-aryl propionate compounds, traditional synthesis methods include Friedel-Crafts alkylation and α-methylation reaction. However, these methods are cumbersome to operate, the functional group compatibility of the substrate is poor, and they are not conducive to industrial-scale production. With the development of transition metal-catalyzed coupling reactions, there are more and more ways to synthesize α-aryl propionate compounds. In 2020, our research group reported the synthesis of such compounds under the synergistic catalytic system of transition metal nickel and visible light. Compared with traditional methods, this method has good substrate tolerance and uses green and environmentally friendly visible light. However, this method requires the use of nickel and visible light, and under their synergistic catalytic action, a certain amount of reducing agent and photocatalyst are added to react to obtain such compounds. However, the present invention, under the catalytic system of a single transition metal cobalt, takes advantage of the substrate Grignard reagent itself as a reducing agent, and can synthesize such compounds by adding a small amount of phosphine ligand.

An improved immediate release solid dosage form of naproxen with a certain particle size distribution for the intragranular portion, and a certain particle size distribution for the carbonate portion that allows naproxen to remain in solution and achieves fast dissolution and fast absorption of naproxen. The invention provides a naproxen dosage form that when administered to a human in a fasted state provides an average blood plasma naproxen concentration of at least 15-20 μg / ml in 10 minutes or less. The invention also provides a naproxen dosage form that when administered to a human in a fed state provides an average blood plasma naproxen concentration of at least 15-20 μg / ml in 50 minutes or less.

The invention discloses an advanced oxidation device and method for degrading new pollutants in water, the device comprises a reaction tank, an ozone generator and a sulfite storage tank, the ozone generator is used for adding ozone into the reaction tank, and the sulfite storage tank is used for adding sulfite into the reaction tank; a water inlet and a water outlet are formed in the reaction tank. During use, a water sample to be treated is injected into the reaction tank, the ozone generator is started, and ozone and sulfite are added into the sulfite storage tank; the adding molar ratio of the ozone to the sulfite in the reaction tank is 5: 1-1: 1, and the molar ratio of the concentration of the new pollutants in the water sample to be treated to the adding amount of the ozone is 1: 10-1: 100. According to the ozone activated sulfite advanced oxidation system constructed by the invention, the yield of sulfate free radicals and hydroxyl free radicals is high, new pollutants can be rapidly degraded within 5 minutes, and the degradation efficiency of new pollutants such as naproxen, sulfamethoxazole, carbamazepine, atrazine, chloramphenicol and the like in water reaches 80% or above.

The present invention is directed to a pharmaceutical composition comprising a pharmaceutically effective amount of guaifenesin, naproxen and at least one further active which is selected to be an antitussive, a decongestant or an antihistamine.

The invention belongs to the technical field of chiral crystalline porous materials and enantiomer separation, and particularly relates to a chiral MOF (Metal Organic Framework) based on L-methionine as well as a preparation method and application thereof. The chiral MOF comprises a zirconium-based MOF matrix and amino acid loaded on the zirconium-based MOF matrix, and the amino acid is L-methionine; carboxyl in the L-methionine is in coordination connection with zirconium ions in the zirconium-based MOF matrix. The prepared MOF-808-LMS is uniformly dispersed in a mixed solvent of normal hexane and isopropanol, and the chiral MOF chromatographic column is prepared based on a homogenization method. The material shows specific chiral recognition capability, and can successfully separate naproxen, ibuprofen and other chiral drug molecules based on HPLC (High Performance Liquid Chromatography).

The invention belongs to the technical field of development of anti-inflammatory drugs, and discloses a naproxen derivative as well as a preparation method and application thereof. The naphthoprim derivative is a compound with a structure as shown in a formula 2 or a pharmaceutically acceptable salt thereof. The naproxen derivative belongs to a novel compound, the compounds are designed and successfully synthesized for the first time, and the structure of the naproxen derivative is represented; the preparation method of the naproxen derivative is simple and convenient to operate, and the compounds can be rapidly synthesized; research finds that the naproxen derivative disclosed by the invention has good anti-inflammatory activity and shows a good application prospect in treatment of inflammation. # imgabs0 #